{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T07:20:02Z","timestamp":1764919202846,"version":"3.46.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T00:00:00Z","timestamp":1734739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T00:00:00Z","timestamp":1734739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100016387","name":"Grifols","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016387","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-024-01528-4","type":"journal-article","created":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T08:58:27Z","timestamp":1734771507000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ex vivo evaluation of the effect of plasma-derived factor VIII\/von Willebrand factor in patients with severe hemophilia A on emicizumab prophylaxis"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-1910-3651","authenticated-orcid":false,"given":"Aida","family":"Ravent\u00f3s","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena G.","family":"Arias-Salgado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alba","family":"P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Teresa","family":"Alvarez-Rom\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nora V.","family":"Butta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Monzon Manzano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Acu\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00edctor","family":"Jim\u00e9nez-Yuste","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Montserrat","family":"Costa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Isabel","family":"Bravo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,21]]},"reference":[{"issue":"9371","key":"1528_CR1","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1016\/s0140-6736(03)13405-8","volume":"361","author":"PH Bolton-Maggs","year":"2003","unstructured":"Bolton-Maggs PH, Pasi KJ. Haemophilias A and B. Lancet. 2003;361(9371):1801\u20139. https:\/\/doi.org\/10.1016\/s0140-6736(03)13405-8.","journal-title":"Lancet"},{"issue":"Suppl 6","key":"1528_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/hae.14046","volume":"26","author":"A Srivastava","year":"2020","unstructured":"Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia. Haemophilia. 2020;26(Suppl 6):1\u2013158. https:\/\/doi.org\/10.1111\/hae.14046.","journal-title":"Haemophilia"},{"issue":"5","key":"1528_CR3","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s10928-019-09637-4","volume":"46","author":"P Chelle","year":"2019","unstructured":"Chelle P, Yeung CHT, Bonanad S, et al. Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi\/Alphanate in hemophilia A patients. J Pharmacokinet Pharmacodyn. 2019;46(5):427\u201338. https:\/\/doi.org\/10.1007\/s10928-019-09637-4.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"23","key":"1528_CR4","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1182\/blood-2017-08-801662","volume":"130","author":"PJ Lenting","year":"2017","unstructured":"Lenting PJ, Denis CV, Christophe OD. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII? Blood. 2017;130(23):2463\u20138. https:\/\/doi.org\/10.1182\/blood-2017-08-801662.","journal-title":"Blood"},{"issue":"9","key":"1528_CR5","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1056\/NEJMoa1803550","volume":"379","author":"J Mahlangu","year":"2018","unstructured":"Mahlangu J, Oldenburg J, Paz-Priel I, et al. Emicizumab prophylaxis in patients who have hemophilia A without Inhibitors. N Engl J Med. 2018;379(9):811\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1803550.","journal-title":"N Engl J Med"},{"issue":"6","key":"1528_CR6","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1182\/blood.2019004334","volume":"136","author":"S Ferri\u00e8re","year":"2020","unstructured":"Ferri\u00e8re S, Peyron I, Christophe OD, et al. A hemophilia A mouse model for the in vivo assessment of emicizumab function. Blood. 2020;136(6):740\u20138. https:\/\/doi.org\/10.1182\/blood.2019004334.","journal-title":"Blood"},{"issue":"6","key":"1528_CR7","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1111\/hae.14172","volume":"26","author":"A Coppola","year":"2020","unstructured":"Coppola A, Castaman G, Santoro RC, et al. Management of patients with severe haemophilia a without inhibitors on prophylaxis with emicizumab: AICE recommendations with focus on emergency in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET. Haemophilia. 2020;26(6):937\u201345. https:\/\/doi.org\/10.1111\/hae.14172.","journal-title":"Haemophilia"},{"issue":"5","key":"1528_CR8","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s12185-020-02959-x","volume":"112","author":"K Ogiwara","year":"2020","unstructured":"Ogiwara K, Nogami K, Matsumoto N, et al. A modified thrombin generation assay to evaluate the plasma coagulation potential in the presence of emicizumab, the bispecific antibody to factors IXa\/X. Int J Hematol. 2020;112(5):621\u201330. https:\/\/doi.org\/10.1007\/s12185-020-02959-x.","journal-title":"Int J Hematol"},{"issue":"8","key":"1528_CR9","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1111\/jth.14887","volume":"18","author":"MI Bravo","year":"2020","unstructured":"Bravo MI, Ravent\u00f3s A, P\u00e9rez A, Costa M, Willis T. Non-additive effect on thrombin generation when a plasma-derived factor VIII\/von Willebrand factor (FVIII\/VWF) is combined with emicizumab in vitro. J Thromb Haemost. 2020;18(8):1934\u20139. https:\/\/doi.org\/10.1111\/jth.14887.","journal-title":"J Thromb Haemost"},{"issue":"9","key":"1528_CR10","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1703068","volume":"377","author":"J Oldenburg","year":"2017","unstructured":"Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with Inhibitors. N Engl J Med. 2017;377(9):809\u201318. https:\/\/doi.org\/10.1056\/NEJMoa1703068.","journal-title":"N Engl J Med"},{"issue":"6","key":"1528_CR11","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1111\/hae.13848","volume":"25","author":"M Shima","year":"2019","unstructured":"Shima M, Nogami K, Nagami S, et al. A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors. Haemophilia. 2019;25(6):979\u201387. https:\/\/doi.org\/10.1111\/hae.13848.","journal-title":"Haemophilia"},{"issue":"4","key":"1528_CR12","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1111\/hae.14005","volume":"26","author":"I McCary","year":"2020","unstructured":"McCary I, Guelcher C, Kuhn J, et al. Real-world use of emicizumab in patients with haemophilia A: bleeding outcomes and surgical procedures. Haemophilia. 2020;26(4):631\u20136. https:\/\/doi.org\/10.1111\/hae.14005.","journal-title":"Haemophilia"},{"issue":"7","key":"1528_CR13","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1160\/th17-01-0030","volume":"117","author":"T Kitazawa","year":"2017","unstructured":"Kitazawa T, Esaki K, Tachibana T, et al. Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX\/IXa and X\/Xa, emicizumab, depends on its ability to bridge the antigens. Thromb Haemost. 2017;117(7):1348\u201357. https:\/\/doi.org\/10.1160\/th17-01-0030.","journal-title":"Thromb Haemost"},{"key":"1528_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/rth2.12227","volume":"3","author":"NKC Ramamurthy","year":"2019","unstructured":"Ramamurthy NKC, McInerney M, Chen D, Morris M. Analytical performance evaluation of a dedicated calibrator and controls for emicizumab quantification orals abstracts. OC 0.74. Res Pract Thromb Haemost. 2019;3:1\u2013228. https:\/\/doi.org\/10.1002\/rth2.12227.","journal-title":"Res Pract Thromb Haemost"},{"issue":"Suppl 5","key":"1528_CR15","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/j.1365-2516.2010.02304.x","volume":"16","author":"SC Nair","year":"2010","unstructured":"Nair SC, Dargaud Y, Chitlur M, Srivastava A. Tests of global haemostasis and their applications in bleeding disorders. Haemophilia. 2010;16(Suppl 5):85\u201392. https:\/\/doi.org\/10.1111\/j.1365-2516.2010.02304.x.","journal-title":"Haemophilia"},{"issue":"2","key":"1528_CR16","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1002\/rth2.12295","volume":"4","author":"S Aghighi","year":"2019","unstructured":"Aghighi S, Riddell A, Lee CA, Brown SA, Tuddenham E, Chowdary P. Global coagulation assays in hemophilia A: a comparison to conventional assays. Res Pract Thromb Haemost. 2019;4(2):298\u2013308. https:\/\/doi.org\/10.1002\/rth2.12295.","journal-title":"Res Pract Thromb Haemost"},{"issue":"3","key":"1528_CR17","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.ejcts.2009.07.038","volume":"37","author":"OM Theusinger","year":"2010","unstructured":"Theusinger OM, N\u00fcrnberg J, Asmis LM, Seifert B, Spahn DR. Rotation thromboelastometry (ROTEM) stability and reproducibility over time. Eur J Cardiothorac Surg. 2010;37(3):677\u201383. https:\/\/doi.org\/10.1016\/j.ejcts.2009.07.038.","journal-title":"Eur J Cardiothorac Surg"},{"issue":"3","key":"1528_CR18","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1046\/j.1538-7836.2003.00075.x","volume":"1","author":"B S\u00f8rensen","year":"2003","unstructured":"S\u00f8rensen B, Johansen P, Christiansen K, Woelke M, Ingerslev J. Whole blood coagulation thrombelastographic profiles employing minimal tissue factor activation. J Thromb Haemost. 2003;1(3):551\u20138. https:\/\/doi.org\/10.1046\/j.1538-7836.2003.00075.x.","journal-title":"J Thromb Haemost"},{"key":"1528_CR19","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.thromres.2023.01.007","volume":"222","author":"T Yamaguchi","year":"2023","unstructured":"Yamaguchi T, Shinozawa K, Nagatoishi S, et al. In vitro validation of chromogenic substrate assay for evaluation of surrogate FVIII-activity of emicizumab. Thromb Res. 2023;222:131\u20139. https:\/\/doi.org\/10.1016\/j.thromres.2023.01.007.","journal-title":"Thromb Res"},{"key":"1528_CR20","doi-asserted-by":"publisher","first-page":"1033416","DOI":"10.3389\/fcvm.2022.1033416","volume":"9","author":"L Valke","year":"2022","unstructured":"Valke L, Rijpma S, Meijer D, Schols SEM, van Heerde WL. Thrombin generation assays to personalize treatment in bleeding and thrombotic diseases. Front Cardiovasc Med. 2022;9:1033416. https:\/\/doi.org\/10.3389\/fcvm.2022.1033416.","journal-title":"Front Cardiovasc Med"},{"issue":"21","key":"1528_CR21","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1056\/NEJMoa1511769","volume":"374","author":"M Shima","year":"2016","unstructured":"Shima M, Hanabusa H, Taki M, et al. Factor VIII-Mimetic function of humanized bispecific antibody in hemophilia A. N Engl J Med. 2016;374(21):2044\u201353. https:\/\/doi.org\/10.1056\/NEJMoa1511769.","journal-title":"N Engl J Med"},{"issue":"6","key":"1528_CR22","doi-asserted-by":"publisher","first-page":"479","DOI":"10.2450\/2019.0211-19","volume":"17","author":"L Aledort","year":"2019","unstructured":"Aledort L, Mannucci PM, Schramm W, Tarantino M. Factor VIII replacement is still the standard of care in haemophilia A. Blood Transfus. 2019;17(6):479\u201386. https:\/\/doi.org\/10.2450\/2019.0211-19.","journal-title":"Blood Transfus"},{"key":"1528_CR23","doi-asserted-by":"publisher","first-page":"100852","DOI":"10.1016\/j.blre.2021.100852","volume":"50","author":"E Berntorp","year":"2021","unstructured":"Berntorp E, Hermans C, Solms A, Poulsen L, Mancuso ME. Optimising prophylaxis in haemophilia A: the ups and downs of treatment. Blood Rev. 2021;50:100852. https:\/\/doi.org\/10.1016\/j.blre.2021.100852.","journal-title":"Blood Rev"},{"issue":"5","key":"1528_CR24","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1111\/hae.14359","volume":"27","author":"H Kizilocak","year":"2021","unstructured":"Kizilocak H, Marquez-Casas E, Malvar J, Carmona R, Young G. Determining the approximate factor VIII level of patients with severe haemophilia A on emicizumab using in vivo global haemostasis assays. Haemophilia. 2021;27(5):730\u20135. https:\/\/doi.org\/10.1111\/hae.14359.","journal-title":"Haemophilia"},{"issue":"7","key":"1528_CR25","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1016\/j.jtha.2024.03.022","volume":"22","author":"L Josset","year":"2024","unstructured":"Josset L, Leuci A, Janbain M, et al. Multicenter evaluation of the hemostatic activity of emicizumab in patients with severe hemophilia A. J Thromb Haemost. 2024;22(7):1857\u201366. https:\/\/doi.org\/10.1016\/j.jtha.2024.03.022.","journal-title":"J Thromb Haemost"},{"issue":"3","key":"1528_CR26","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1160\/th04-10-0706","volume":"93","author":"Y Dargaud","year":"2005","unstructured":"Dargaud Y, B\u00e9guin S, Lienhart A, et al. Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B. Thromb Haemost. 2005;93(3):475\u201380. https:\/\/doi.org\/10.1160\/th04-10-0706.","journal-title":"Thromb Haemost"},{"issue":"12","key":"1528_CR27","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1161\/01.ATV.0000187463.91403.b2","volume":"25","author":"J Jesty","year":"2005","unstructured":"Jesty J, Beltrami E. Positive feedbacks of coagulation: their role in threshold regulation. Arterioscler Thromb Vasc Biol. 2005;25(12):2463\u20139. https:\/\/doi.org\/10.1161\/01.ATV.0000187463.91403.b2.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"7","key":"1528_CR28","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1111\/jth.14135","volume":"16","author":"K Nogami","year":"2018","unstructured":"Nogami K, Soeda T, Matsumoto T, Kawabe Y, Kitazawa T, Shima M. Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies. J Thromb Haemost. 2018;16(7):1383\u201390. https:\/\/doi.org\/10.1111\/jth.14135.","journal-title":"J Thromb Haemost"},{"issue":"6","key":"1528_CR29","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1111\/jth.14022","volume":"16","author":"K Nogami","year":"2018","unstructured":"Nogami K, Matsumoto T, Tabuchi Y, et al. Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa\/factor X bispecific antibody emicizumab. J Thromb Haemost. 2018;16(6):1078\u201388. https:\/\/doi.org\/10.1111\/jth.14022.","journal-title":"J Thromb Haemost"},{"issue":"1","key":"1528_CR30","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12959-015-0038-0","volume":"13","author":"EN Lipets","year":"2015","unstructured":"Lipets EN, Ataullakhanov FI. Global assays of hemostasis in the diagnostics of hypercoagulation and evaluation of thrombosis risk. Thromb J. 2015;13(1):4. https:\/\/doi.org\/10.1186\/s12959-015-0038-0.","journal-title":"Thromb J"},{"issue":"6","key":"1528_CR31","doi-asserted-by":"publisher","first-page":"e295","DOI":"10.1016\/s2352-3026(19)30054-7","volume":"6","author":"SW Pipe","year":"2019","unstructured":"Pipe SW, Shima M, Lehle M, et al. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Lancet Haematol. 2019;6(6):e295\u2013305. https:\/\/doi.org\/10.1016\/s2352-3026(19)30054-7.","journal-title":"Lancet Haematol"},{"key":"1528_CR32","unstructured":"Foundation NH. Recommendation on the use and management of emicizumabkxwh (Hemlibra\u00ae) for hemophilia A with and without inhibitors. MASAC Document #258. Accessed May 2022."},{"issue":"5","key":"1528_CR33","doi-asserted-by":"publisher","first-page":"e12561","DOI":"10.1002\/rth2.12561","volume":"5","author":"NH Schultz","year":"2021","unstructured":"Schultz NH, Glosli H, Bj\u00f8rnsen S, Holme PA. The effect of emicizumab and bypassing agents in patients with hemophilia\u2013an in vitro study. Res Pract Thromb Haemost. 2021;5(5):e12561. https:\/\/doi.org\/10.1002\/rth2.12561.","journal-title":"Res Pract Thromb Haemost"},{"issue":"1","key":"1528_CR34","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/hae.14213","volume":"27","author":"H Kizilocak","year":"2021","unstructured":"Kizilocak H, Marquez-Casas E, Phei Wee C, Malvar J, Carmona R, Young G. Comparison of bypassing agents in patients on emicizumab using global hemostasis assays. Haemophilia. 2021;27(1):164\u201372. https:\/\/doi.org\/10.1111\/hae.14213.","journal-title":"Haemophilia"},{"key":"1528_CR35","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1111\/jth.14203","volume":"16","author":"R Hartmann","year":"2018","unstructured":"Hartmann R, Feenstra T, Valentino L, Dockal M, Scheiflinger F. In vitro studies show synergistic effects of a procoagulant bispecific antibody and bypassing agents. J Thromb Haemost. 2018;16:1580. https:\/\/doi.org\/10.1111\/jth.14203.","journal-title":"J Thromb Haemost"},{"issue":"1","key":"1528_CR36","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1111\/hae.14684","volume":"29","author":"H Kizilocak","year":"2023","unstructured":"Kizilocak H, Marquez-Casas E, Malvar J, Young G. Safety of FEIBA and emicizumab (SAFE): Dose escalation study evaluating the safety of in vivo administration of activated prothrombin complex concentrate in haemophilia A patients on emicizumab. Haemophilia. 2023;29(1):100\u20135. https:\/\/doi.org\/10.1111\/hae.14684.","journal-title":"Haemophilia"},{"issue":"9","key":"1528_CR37","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1111\/jth.14491","volume":"17","author":"GG Levy","year":"2019","unstructured":"Levy GG, Asikanius E, Kuebler P, Benchikh-El-Fegoun S, Esbjerg S, Seremetis S. Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: experience from the HAVEN clinical program. J Thromb Haemost. 2019;17(9):1470\u20137. https:\/\/doi.org\/10.1111\/jth.14491.","journal-title":"J Thromb Haemost"},{"issue":"5","key":"1528_CR38","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1160\/th03-10-0638","volume":"91","author":"GT Gerotziafas","year":"2004","unstructured":"Gerotziafas GT, Chakroun T, Depasse F, Arzoglou P, Samama MM, Elalamy I. The role of platelets and recombinant factor VIIa on thrombin generation, platelet activation and clot formation. Thromb Haemost. 2004;91(5):977\u201385. https:\/\/doi.org\/10.1160\/th03-10-0638.","journal-title":"Thromb Haemost"},{"issue":"9","key":"1528_CR39","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1055\/s-0039-1692427","volume":"119","author":"J M\u00fcller","year":"2019","unstructured":"M\u00fcller J, Pekrul I, P\u00f6tzsch B, Berning B, Oldenburg J, Spannagl M. Laboratory monitoring in emicizumab-treated persons with hemophilia A. Thromb Haemost. 2019;119(9):1384\u201393. https:\/\/doi.org\/10.1055\/s-0039-1692427.","journal-title":"Thromb Haemost"},{"issue":"4","key":"1528_CR40","doi-asserted-by":"publisher","first-page":"e181","DOI":"10.3324\/haematol.2017.185330","volume":"103","author":"Y Dargaud","year":"2018","unstructured":"Dargaud Y, Lienhart A, Janbain M, Le Quellec S, Enjolras N, Negrier C. Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab. Haematologica. 2018;103(4):e181\u20133. https:\/\/doi.org\/10.3324\/haematol.2017.185330.","journal-title":"Haematologica"},{"issue":"2","key":"1528_CR41","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1002\/ajh.25319","volume":"94","author":"S Ramiz","year":"2019","unstructured":"Ramiz S, Hartmann J, Young G, Escobar MA, Chitlur M. Clinical utility of viscoelastic testing (TEG and ROTEM analyzers) in the management of old and new therapies for hemophilia. Am J Hematol. 2019;94(2):249\u201356. https:\/\/doi.org\/10.1002\/ajh.25319.","journal-title":"Am J Hematol"},{"issue":"1","key":"1528_CR42","doi-asserted-by":"publisher","first-page":"100018","DOI":"10.1016\/j.rpth.2022.100018","volume":"7","author":"RF Sidonio Jr","year":"2023","unstructured":"Sidonio RF Jr, Hoffman M, Kenet G, Dargaud Y. Thrombin generation and implications for hemophilia therapies: a narrative review. Res Pract Thromb Haemost. 2023;7(1):100018. https:\/\/doi.org\/10.1016\/j.rpth.2022.100018.","journal-title":"Res Pract Thromb Haemost"},{"issue":"4","key":"1528_CR43","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/bjh.14148","volume":"174","author":"K Nogami","year":"2016","unstructured":"Nogami K. The utility of thromboelastography in inherited and acquired bleeding disorders. Br J Haematol. 2016;174(4):503\u201314. https:\/\/doi.org\/10.1111\/bjh.14148.","journal-title":"Br J Haematol"},{"issue":"11","key":"1528_CR44","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1111\/j.1538-7836.2004.00964.x","volume":"2","author":"R Luddington","year":"2004","unstructured":"Luddington R, Baglin T. Clinical measurement of thrombin generation by calibrated automated thrombography requires contact factor inhibition. J Thromb Haemost. 2004;2(11):1954\u20139. https:\/\/doi.org\/10.1111\/j.1538-7836.2004.00964.x.","journal-title":"J Thromb Haemost"},{"issue":"Suppl 1","key":"1528_CR45","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1097\/mbc.0000000000001108","volume":"33","author":"I Fernandez-Bello","year":"2022","unstructured":"Fernandez-Bello I. Monitoring of new therapies for hemophilia. Blood Coagul Fibrinolysis. 2022;33(Suppl 1):S3\u20134. https:\/\/doi.org\/10.1097\/mbc.0000000000001108.","journal-title":"Blood Coagul Fibrinolysis"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-024-01528-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-024-01528-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-024-01528-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:48:37Z","timestamp":1764917317000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-024-01528-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,21]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1528"],"URL":"https:\/\/doi.org\/10.1007\/s10238-024-01528-4","relation":{},"ISSN":["1591-9528"],"issn-type":[{"type":"electronic","value":"1591-9528"}],"subject":[],"published":{"date-parts":[[2024,12,21]]},"assertion":[{"value":"1 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Aida Ravent\u00f3s, Alba P\u00e9rez, Montserrat Costa and Mar\u00eda-Isabel Bravo are full-time employees of Grifols and have no other competing interests to declare. V\u00edctor Jim\u00e9nez-Yuste received reimbursement for attending symposia\/congresses and\/or honoraria for speaking and\/or honoraria for consulting, and\/or funds for research from Shire, Bayer, CSL-Behring, Grifols, Novo Nordisk, Sobi, Octapharma, BioMarin, Sanofi and Pfizer. Mar\u00eda Teresa \u00c1lvarez-Rom\u00e1n received reimbursement for attending symposia and\/or honoraria for speaking and\/or honoraria for consulting, and\/or funds for research from Takeda, Bayer, CSL-Behring, Grifols, Novo Nordisk, Sobi, Octapharma, BioMarin, Novartis, Amgen and Pfizer. Elena G. Arias-Salgado received reimbursement for attending symposia\/congresses and\/or honoraria for speaking, and\/or funds for research from Bayer, CSL-Behring, Grifols, Novartis and Novo Nordisk. Nora V. Butta received reimbursement for attending symposia\/congresses and\/or honoraria for speaking, and\/or funds for research from Pfizer, Amgen, CSL-Behring, Grifols, Novartis and Novo Nordisk. Elena Monz\u00f3n Manzano and Paula Acu\u00f1a received reimbursement for attending symposia\/congresses from Takeda, Novartis and Novo Nordisk.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The ethical approval to report this study was obtained from the ethics committee of Hospital Universitario la Paz, Madrid, Spain (ID number: HULP PI-4320), before the study was initiated.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}}],"article-number":"14"}}